What the studies answer and what this site can't do
What can CJC-1295 Medicine help you check?
Human studies measured blood hormones and short-term harm. They didn't prove that CJC-1295 helped people feel better. This site explains those limits but can't provide care.
Which claims can you check here?
CJC-1295 Medicine explains what human studies found. Results from rats or cells are marked as such. The site also names questions nobody tested. A note number by a claim leads to the paper behind it.
CJC-1295 Medicine isn't a clinic and has no doctor on staff. It doesn't prescribe, give medical advice, make, sell, or ship a product. The CJC-1295 Medicine name doesn't mean you can get care here.
I'd use these pages to check a claim, not to choose for you. Your doctor knows your health.
Who made the drug, and why did testing end?
ConjuChem Inc., a drug company in Montreal, made CJC-1295 in the early 2000s [02][03]. Its long form attached to albumin, a protein that carries substances in your blood. That longer stay made a weekly shot seem possible [12].
In 2005, researchers tested three forms in rats and rat growth-gland cells. CJC-1295 caused the strongest growth hormone release. In 2006, a stage 1 paper from the first human testing stage found that half the drug remained across a 5.8- to 8.1-day span in healthy adults [01][03].
A stage 2 record on ClinicalTrials.gov describes a later study of weekly amounts in people with HIV and extra fat around their organs [18], and about 192 people joined before it stopped. In 2006, one person died from a heart attack. His doctor said heart disease already present, not the drug, caused the death [07]. ConjuChem then ended work on its group of long-form drugs. No large late-stage CJC-1295 study has restarted in the twenty years since.
Those dates can't tell you what your body would face, how you'd feel, or whether your health would improve.
How many trials involved people?
Public records show at least four stage 1 trials and trials labeled stage 1/2. That label means the test combined the first safety stage with an early check for benefit. Two rising-amount stage 1 trials in healthy adults were reported in 2006 [01]. The records also list the stopped stage 2 study in people with HIV and extra belly fat [18].
Human testing never resumed. The 2006 paper is still the main published human report on CJC-1295. The stage 2 record says what researchers planned but gives no results. That stage 2 record can describe the plan, not what happened, because its findings were never published.
The CJC-1295 human record is thin. It can't tell you what years of use would mean for your health.
What do public records say happened after the death?
A public report says one person's death in 2006 helped lead ConjuChem to stop work on its group of long-form drugs during stage 2 [07]. That group included CJC-1295. No published report tied the drug to the death. The treating doctor blamed heart disease already present.
No large late test followed. No stage 2 results showed whether the drug worked. No public report tracked years of checkups, blood tests, or harm. We can't guess what the missing work would have found.
Those dates don't tell you what the drug would do in your body or to your health.
What kind of help isn't offered here?
This site doesn't make, sell, or ship CJC-1295 or any other peptide, meaning a short chain of amino acids. It gives no dose or medical advice. No doctors, pharmacists, or other health workers are on staff. You can't get treatment, a doctor visit, or a prescription here. You can read what the papers found and check the source for each number.
Open references and citations to see the papers. If a date, number, or source looks wrong, use the contact page. For a health choice, speak with your own doctor, who knows your full history.